DelveInsight’s, “Lupus Nephritis Pipeline Insight 2023” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the Lupus Nephritis pipeline landscape. It covers the Lupus Nephritis pipeline drug profiles, including Lupus Nephritis clinical trials and nonclinical stage products. It also covers the Lupus Nephritis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Lupus Nephritis Pipeline Report
- DelveInsight’s Lupus Nephritis pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Lupus Nephritis treatment.
- The leading companies working in the Lupus Nephritis Market include Roche, Horizon Therapeutics, Equillium, Argenx, AstraZeneca, Novartis, RemeGen, Annexon, and others.
- Promising Lupus Nephritis Pipeline Therapies in the various stages of development include Obinutuzumab, Mycophenolate Mofetil, Anifrolumab, Cyclophosphamide, Azathioprine, and others.
- September 2023: Novartis Pharmaceuticals announced a study of phase 3 clinical trials for Secukinumab. The purpose is to provide treatment with secukinumab delivered subcutaneously (s.c.) via pre-filled syringe (PFS) for participants who complete study treatment until the Week 104 of the core study CAIN457Q12301 and to obtain long-term efficacy, safety and tolerability data.
- September 2023: Kezar Life Sciences Inc. announced a study of phase 2 clinical trials for Zetomipzomib. The purpose of this study is to assess the efficacy and safety of zetomipzomib (30 mg or 60 mg) compared with placebo in achieving renal response after 52 weeks of treatment in patients with active lupus nephritis (LN).
Request a sample and discover the recent advances in Lupus Nephritis Treatment Drugs @ Lupus Nephritis Pipeline Report
In the Lupus Nephritis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Lupus Nephritis clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Lupus Nephritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Lupus Nephritis Overview
Lupus Nephritis (LN) is one of the most severe organ manifestations of systemic lupus erythematosus (SLE), which is an autoimmune disorder leading to the loss of immune tolerance of endogenous nuclear material, resulting in systemic autoimmunity that causes damage to various tissues and organs. According to the National Kidney Foundation, Lupus nephritis (LN) is a form of glomerulonephritis that causes inflammation (swelling or scarring) of the small blood vessels that filter wastes in the kidney (glomeruli) and sometimes the kidney itself. Histologically, LN is classified into six distinct classes, representing different manifestations and severity of renal involvement in SLE.
Find out more about Lupus Nephritis Therapeutics Assessment @ Lupus Nephritis Preclinical and Discovery Stage Products
Lupus Nephritis Emerging Drugs Profile
- Obinutuzumab: Roche
- Daxdilimab: Horizon Therapeutics
- Itolizumab: Equillium
Lupus Nephritis Pipeline Therapeutics Assessment
There are approx. 20+ key companies which are developing the Lupus Nephritis therapies. The Lupus Nephritis companies which have their Lupus Nephritis drug candidates in the most advanced stage, i.e. Phase III include, Roche.
Learn more about the emerging Lupus Nephritis Pipeline Therapies @ Lupus Nephritis Clinical Trials Assessment
Scope of the Lupus Nephritis Pipeline Report
- Coverage- Global
- Lupus Nephritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Lupus Nephritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Lupus Nephritis Companies- Roche, Horizon Therapeutics, Equillium, Argenx, AstraZeneca, Novartis, RemeGen, Annexon, and others.
- Lupus Nephritis Pipeline Therapies- Obinutuzumab, Mycophenolate Mofetil, Anifrolumab, Cyclophosphamide, Azathioprine, and others.
Dive deep into rich insights for new drugs for Lupus Nephritis Treatment, Visit @ Lupus Nephritis Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Lupus Nephritis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Lupus Nephritis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Obinutuzumab: Roche
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Daxdilimab: Horizon Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Itolizumab: Equillium
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Lupus Nephritis Key Companies
- Lupus Nephritis Key Products
- Lupus Nephritis- Unmet Needs
- Lupus Nephritis- Market Drivers and Barriers
- Lupus Nephritis- Future Perspectives and Conclusion
- Lupus Nephritis Analyst Views
- Lupus Nephritis Key Companies
- Appendix
For further information on the Lupus Nephritis Pipeline therapeutics, reach out to Lupus Nephritis Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking